Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Elekta AB (OTC: EKTAF).

Full DD Report for EKTAF

You must become a subscriber to view this report.


Recent News from (OTC: EKTAF)

Elekta AB (EKTAF) CEO Richard Hausmann on Q2 2019 Results - Earnings Call Transcript
Elekta AB (EKTAF) Q2 2019 Results Earnings Conference Call November 29, 2018, 04:00 AM ET Executives Gunilla Öhman - Interim IR Manager Gustaf Salford - CFO Richard Hausmann - CEO Analysts Annette Lykke - Handelsbanken Sebastian Walker - UBS Michael Jungling - Morg...
Source: SeekingAlpha
Date: November, 29 2018 10:39
Elekta AB 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Elekta AB in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: November, 29 2018 09:59
Elekta AB reports Q2 results
Elekta AB ( OTCPK:EKTAF ): Q2 GAAP EPS of SEK0.75. More news on: Elekta AB, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 29 2018 05:58
Elekta Wins User-centered Product Design Award for its MR-linac, Elekta Unity
PHILADELPHIA , Oct. 3, 2018 /PRNewswire/ -- Elekta (EKTA-B.ST) and DCA Design International Ltd have won the prestigious Human Factors and Ergonomics Society (HFES) Stanley H. Caplan User-Centered Product Design Award 2018 for Elekta Unity, Elekta's MR-linac. Elekta Unity combines high-fi...
Source: PR Newswire
Date: October, 03 2018 08:42
Precision Cancer Therapy With Elekta Unity now Available in the UK at The Royal Marsden and The Institute of Cancer Research, London
LONDON , Sept. 25, 2018 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that The Royal Marsden and The Institute of Cancer Research (ICR), London , have clinically implemented Elekta Unity, a transformative magnetic resonance radiation therapy (MR/RT) system that ushers radiotherapy i...
Source: PR Newswire
Date: September, 25 2018 01:56
UK's NHS Supply Chain Orders Elekta Brachytherapy Equipment for Accurate Cancer Treatment
CRAWLEY, England , Sept. 19, 2018 /PRNewswire/ -- Elekta announced today that the UK's National Health Service (NHS) will acquire 10 Flexitron® afterloading platforms used to treat a variety of the most common cancers with brachytherapy. The systems have been ordered by the ...
Source: PR Newswire
Date: September, 19 2018 02:09
Magnetic Resonance Radiation Therapy With Elekta Unity is now in Clinical use at The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
AMSTERDAM , Sept. 7, 2018 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that Elekta Unity, its transformative magnetic resonance radiation therapy (MR/RT) system, is now in clinical use at The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AvL). Elekta Unity is the...
Source: PR Newswire
Date: September, 07 2018 02:05
Elekta Celebrates Inauguration of New Global Radiotherapy Innovation Center
UK's Cornerstone facility designed as an international hub for the design, development and manufacturing of advanced cancer treatment solutions CRAWLEY, United Kingdom , Sept. 5, 2018 /PRNewswire/ -- Elekta employees joined national and local political representatives and disting...
Source: PR Newswire
Date: September, 05 2018 02:03
Elekta AB reports Q1 results
Elekta AB ( OTCPK:EKTAF ): Q1 GAAP EPS of SEK0.43. Revenue of SEK2.82B (+12.8% Y/Y) Press Release More news on: Elekta AB, Elekta AB ADR, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: August, 30 2018 08:26
First Patient Treated With CE-marked Elekta Unity at University Medical Center Utrecht
Milestone heralds the age of personalized and precision radiation medicine for cancer patients in Europe UTRECHT, The Netherlands , Aug. 22, 2018 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that the University Medical Center (UMC) Utrecht has started treating cancer patient...
Source: PR Newswire
Date: August, 22 2018 06:19

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1412.4612.4612.4612.462,080
2018-12-1312.6912.6512.6912.65666
2018-12-1212.704912.704912.704912.70492,876
2018-12-1112.4012.4012.4012.40500
2018-12-1012.6512.652412.652412.653,846

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14802,0803.8462Cover
2018-12-1316666624.9249Cover
2018-12-077001,70041.1765Short
2018-12-04100100100.0000Short
2018-12-032,5704,49457.1874Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EKTAF.


About Elekta AB (OTC: EKTAF)

Logo for Elekta AB (OTC: EKTAF)

The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.

 

Contact Information

 

 

Current Management

  • Tomas Puusepp / CEO, President
  • Johan Sedihn / COO
  • Hakan Bergstrom / CFO

Current Share Structure

     


    Recent Filings from (OTC: EKTAF)

    Post-effective amendment to a previously filed F-6
    Filing Type: F-6 POSFiling Source: edgar
    Filing Date: September, 29 2017

     

     


    Daily Technical Chart for (OTC: EKTAF)

    Daily Technical Chart for (OTC: EKTAF)


    Stay tuned for daily updates and more on (OTC: EKTAF)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: EKTAF)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EKTAF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EKTAF and does not buy, sell, or trade any shares of EKTAF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/